{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:58:52Z","timestamp":1787065132570,"version":"build-2736575974"},"reference-count":272,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica de la Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Leon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"University of Salamanca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008318","name":"Asociaci\u00f3n Espa\u00f1ola Para el Estudio del H\u00edgado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.bcp.2024.116166","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T19:24:03Z","timestamp":1711308243000},"page":"116166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-6849","authenticated-orcid":false,"given":"Jose J.G.","family":"Marin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candela","family":"Cives-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta R.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca P.","family":"Marijuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazaret","family":"Hortelano-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Delgado-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Gonzalez-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitane","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116166_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-981-13-7647-4_3","article-title":"SLC family transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061663","article-title":"Molecular bases of drug resistance in Hepatocellular Carcinoma","volume":"12","author":"Marin","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/ SLC21 family: phylogenetic classification as OATP\/ SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(02)00633-8","article-title":"The superfamily of organic anion transporting polypeptides","volume":"1609","author":"Hagenbuch","year":"2003","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00232-005-7004-x","article-title":"Organic anion transporting polypeptides of the OATP\/SLCO superfamily: identification of new members in nonmammalian species, comparative modeling and a potential transport mode","volume":"208","author":"Meier-Abt","year":"2005","journal-title":"J Membr Biol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0030","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41467-023-41552-8","article-title":"Structure of human drug transporters OATP1B1 and OATP1B3","volume":"14","author":"Ciuta","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b0035","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41422-023-00870-8","article-title":"Cryo-EM structures of human organic anion transporting polypeptide OATP1B1","volume":"33","author":"Shan","year":"2023","journal-title":"Cell Res"},{"issue":"41","key":"10.1016\/j.bcp.2024.116166_b0040","doi-asserted-by":"crossref","first-page":"30326","DOI":"10.1074\/jbc.M602048200","article-title":"OATP8\/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes?","volume":"281","author":"Briz","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0045","doi-asserted-by":"crossref","first-page":"C570","DOI":"10.1152\/ajpcell.00436.2008","article-title":"Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters","volume":"296","author":"Leuthold","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0050","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/mol.110.069971","article-title":"Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3","volume":"79","author":"Martinez-Becerra","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2024.116166_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-pharmtox-010510-100556","article-title":"The expression and function of organic anion transporting polypeptides in normal tissues and in cancer","volume":"52","author":"Obaidat","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0070","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/dmd.114.062034","article-title":"Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue","volume":"43","author":"Badee","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b0075","doi-asserted-by":"crossref","first-page":"9610","DOI":"10.1074\/jbc.M411092200","article-title":"Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry","volume":"280","author":"Lee","year":"2005","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/14622416.10.3.339","article-title":"Pharmacogenetics of the organic anion transporting polypeptide 1A2","volume":"10","author":"Franke","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0085","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1172\/JCI118897","article-title":"Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT)","volume":"98","author":"Lu","year":"1996","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/bbrc.2000.2922","article-title":"Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family","volume":"273","author":"Tamai","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0095","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.107.014902","article-title":"Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines","volume":"35","author":"Hilgendorf","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0110","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0120","doi-asserted-by":"crossref","first-page":"G271","DOI":"10.1152\/ajpgi.00075.2007","article-title":"Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport","volume":"293","author":"Mahagita","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2024.116166_b0125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1042\/bj20030034","article-title":"Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin","volume":"371","author":"Briz","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.bcp.2024.116166_b0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/B978-0-12-800223-0.00005-0","article-title":"Organic anion-transporting polypeptides","volume":"73","author":"Stieger","year":"2014","journal-title":"Curr Top Membr"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clpt.2006.09.010","article-title":"Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart","volume":"80","author":"Grube","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0140","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1248\/bpb.b14-00767","article-title":"Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs","volume":"38","author":"Maeda","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0145","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1389200222666210114122729","article-title":"HMG-CoA reductase inhibitors (statins) and their drug Interactions involving CYP enzymes","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"P-Glycoprotein and OATP Transporters-an Overview, Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0155","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/clpt.2008.94","article-title":"Influence of solute carriers on the pharmacokinetics of CYP3A4 probes","volume":"84","author":"Franke","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0160","first-page":"866","article-title":"OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","volume":"27","author":"Cvetkovic","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1124\/dmd.107.017814","article-title":"Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans","volume":"36","author":"Matsushima","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/jpet.106.104364","article-title":"Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants","volume":"318","author":"Badagnani","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/dmd.32.3.291","article-title":"Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity","volume":"32","author":"Nozawa","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/FPC.0b013e328335b02d","article-title":"HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms","volume":"20","author":"Hartkoorn","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0190","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.106.103390","article-title":"Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers","volume":"318","author":"Liu","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0195","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/dmd.105.008888","article-title":"OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker","volume":"34","author":"Nakagomi-Hagihara","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0200","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0205","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bbamem.2009.03.003","article-title":"Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells","volume":"1788","author":"Seki","year":"2009","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/mol.111.074823","article-title":"Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1)","volume":"81","author":"Visentin","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b0215","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2024.116166_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2362.33.s2.5.x","article-title":"Organic anion-transporting polypeptide (OATP) transporter family and drug disposition","volume":"33","author":"Kim","year":"2003","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0225","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cbpc.2003.12.004","article-title":"Molecular cloning and functional characterization of the bovine (Bos taurus) organic anion transporting polypeptide Oatp1a2 (Slco1a2)","volume":"137","author":"Geyer","year":"2004","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"issue":"3\u20134","key":"10.1016\/j.bcp.2024.116166_b0230","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000381313","article-title":"Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition","volume":"95","author":"Zhou","year":"2015","journal-title":"Pharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.116.105544","article-title":"Contribution of organic anion-transporting polypeptides 1A\/1B to doxorubicin uptake and Clearance","volume":"91","author":"Lee","year":"2017","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0240","doi-asserted-by":"crossref","first-page":"e13792","DOI":"10.1371\/journal.pone.0013792","article-title":"Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1\/OATP1B1 in flavopiridol disposition","volume":"5","author":"Ni","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0245","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/dmd.104.001909","article-title":"Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms","volume":"33","author":"Nozawa","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0250","first-page":"1","article-title":"Organic anion transporting polypeptide (OATP)2B1 contributes to gastrointestinal toxicity of anticancer drug SN-38","volume":"44","author":"Fujita","year":"2016","journal-title":"Active Metabolite of Irinotecan Hydrochloride, Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0255","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s11095-017-2241-0","article-title":"Role of the OATP transporter family and a Benzbromarone-SensitiveEfflux transporter in the Hepatocellular disposition of vincristine","volume":"34","author":"Nicolai","year":"2017","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/clpt.2011.102","article-title":"Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia","volume":"90","author":"Yamakawa","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2024.116166_b0265","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bcpt.13635","article-title":"Contribution of membrane transporters to chemotherapy-induced cardiotoxicity","volume":"130","author":"Uddin","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0270","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-12-0926","article-title":"Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics","volume":"12","author":"Lancaster","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2024.116166_b0275","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2007.10.040","article-title":"Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes","volume":"260","author":"Yamaguchi","year":"2008","journal-title":"Cancer Lett"},{"issue":"16","key":"10.1016\/j.bcp.2024.116166_b0280","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1158\/1078-0432.CCR-12-0761","article-title":"Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel","volume":"18","author":"de Graan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.28970","article-title":"Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel","volume":"136","author":"Iusuf","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0290","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1535-7163.MCT-14-0547","article-title":"Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance","volume":"14","author":"Lee","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0295","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.biopha.2011.04.031","article-title":"Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport","volume":"65","author":"Svoboda","year":"2011","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0300","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1158\/0008-5472.CAN-13-3634","article-title":"Influence of drug formulation on OATP1B-mediated transport of paclitaxel","volume":"74","author":"Nieuweboer","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.61.4.853","article-title":"Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells","volume":"61","author":"Briz","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0310","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s12272-011-1107-y","article-title":"Role of transporters in drug interactions","volume":"34","author":"Han","year":"2011","journal-title":"Arch Pharm Res"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2125.2011.03972.x","article-title":"Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers","volume":"72","author":"Allred","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0320","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1038\/bjc.2017.217","article-title":"Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations","volume":"117","author":"Hu","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0325","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0330","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0335","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP1747","article-title":"Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir\/ritonavir","volume":"16","author":"de Kanter","year":"2011","journal-title":"Antivir Ther"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b0340","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/00498250500136676","article-title":"Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport","volume":"35","author":"Yamazaki","year":"2005","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/lt.22225","article-title":"Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia","volume":"17","author":"Moreno","year":"2011","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0350","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0355","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","article-title":"Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects","volume":"81","author":"van Giersbergen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 5","key":"10.1016\/j.bcp.2024.116166_b0360","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/00005344-198608005-00024","article-title":"Adrenaline responsiveness in borderline hypertension","volume":"8","author":"Hjemdahl","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0365","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1124\/dmd.112.048330","article-title":"Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects","volume":"41","author":"Kusuhara","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0370","first-page":"74","article-title":"New strategies to address drug-drug interactions involving OATPs","volume":"10","author":"Poirier","year":"2007","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0375","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.119.257600","article-title":"Quantitative contribution of six major transporters to the hepatic uptake of drugs: \u201cSLC-phenotyping\u201d using Primary human hepatocytes","volume":"370","author":"Bi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b0380","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0385","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1124\/dmd.105.005926","article-title":"Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators","volume":"33","author":"Wang","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.123.001754","article-title":"A novel approach to predicting organic anion transporting polypeptide function in human hepatic drug disposition and Biliary Clearance","volume":"387","author":"Lash","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mcp.2002.121152","article-title":"Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine","volume":"71","author":"Dresser","year":"2002","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0400","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1124\/dmd.104.002337","article-title":"Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B","volume":"33","author":"Satoh","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0405","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.coph.2013.09.001","article-title":"OATP transporter-mediated drug absorption and interaction","volume":"13","author":"Tamai","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0410","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/clpt.2012.159","article-title":"Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides","volume":"92","author":"Dolton","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2024.116166_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119975","article-title":"Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis","volume":"291","author":"Zechner","year":"2022","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0420","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cpt.1112","article-title":"Transporters in drug development: 2018 ITC recommendations for transporters of Emerging clinical importance","volume":"104","author":"Zamek-Gliszczynski","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dmpk.2019.11.004","article-title":"Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters","volume":"35","author":"Nozaki","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"issue":"38","key":"10.1016\/j.bcp.2024.116166_b0430","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among european- and african-Americans","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0435","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/17425255.2012.656087","article-title":"Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions","volume":"8","author":"Clarke","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b0440","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0445","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0450","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bcp.2024.116166_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115681","article-title":"Relevance of the organic anion transporting polypeptide 1B3 (OATP1B3) in the personalized pharmacological treatment of hepatocellular carcinoma","volume":"214","author":"Asensio","year":"2023","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b0460","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1017\/S0007114511002273","article-title":"Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases","volume":"106","author":"Macias","year":"2011","journal-title":"Br J Nutr"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0465","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cpt.1717","article-title":"Protein abundance of hepatic drug transporters in patients with different forms of liver damage","volume":"107","author":"Drozdzik","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0470","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1124\/dmd.116.071050","article-title":"Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by Targeted quantitative proteomics","volume":"44","author":"Wang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0475","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b0480","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0485","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1038\/s41467-023-42086-9","article-title":"Structural basis of promiscuous substrate transport by organic cation transporter 1","volume":"14","author":"Zeng","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0490","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1038\/s41467-022-34284-8","article-title":"Structural basis of organic cation transporter-3 inhibition","volume":"13","author":"Khanppnavar","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0500","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/mol.63.3.489","article-title":"Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1","volume":"63","author":"Bednarczyk","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0505","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/bdd.684","article-title":"A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes","volume":"30","author":"Sogame","year":"2009","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0510","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/hep.23103","article-title":"Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver","volume":"50","author":"Nies","year":"2009","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0515","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00498250701546012","article-title":"Functional involvement of organic cation transporter1 (OCT1\/Oct1) in the hepatic uptake of organic cations in humans and rats","volume":"37","author":"Umehara","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bcp.2024.116166_b0520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handbook of experimental pharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0525","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/hep.26425","article-title":"Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib","volume":"58","author":"Herraez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2024.116166_b0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115812","article-title":"Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors","volume":"217","author":"Herraez","year":"2023","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0535","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3892\/ijo.2013.1840","article-title":"Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma","volume":"42","author":"Lautem","year":"2013","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0540","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/bcp.12476","article-title":"Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers","volume":"78","author":"Cho","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0545","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bcpt.12579","article-title":"Early discontinuation of metformin in individuals treated with inhibitors of transporters of metformin","volume":"118","author":"Stage","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0550","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1023\/A:1025032511040","article-title":"pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions","volume":"20","author":"Neuhoff","year":"2003","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0555","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2472555218812821","article-title":"OCTN: a small transporter subfamily with great relevance to human pathophysiology","volume":"24","author":"Pochini","year":"2019","journal-title":"Drug Discovery, and Diagnostics, SLAS Discovery : Advancing Life Sciences R & D"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0560","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.bbamem.2011.12.014","article-title":"The human OCTN1 (SLC22A4) reconstituted in liposomes catalyzes acetylcholine transport which is defective in the mutant L503F associated to the crohn's disease","volume":"1818","author":"Pochini","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0565","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1158\/0008-5472.CAN-16-2548","article-title":"OCTN1 is a high-affinity Carrier of nucleoside analogues","volume":"77","author":"Drenberg","year":"2017","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b0570","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/AAC.00986-16","article-title":"Multiple drug transporters are involved in renal secretion of entecavir","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b0575","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00512-18","article-title":"Comprehensive substrate Characterization of 22 antituberculosis drugs for multiple solute Carrier (SLC) uptake transporters in vitro","volume":"62","author":"Parvez","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0580","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.clpt.6100271","article-title":"Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin","volume":"83","author":"Urban","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0585","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41598-017-01438-4","article-title":"Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts","volume":"7","author":"Harrach","year":"2017","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0590","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1535-7163.MCT-11-0980","article-title":"Inhibition of OCTN2-mediated transport of carnitine by etoposide","volume":"11","author":"Hu","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0595","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/17425255.2021.1915284","article-title":"Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing","volume":"17","author":"Koepsell","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.bcp.2024.116166_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108268","article-title":"Hepatic solute carrier transporters and drug therapy: regulation of expression and impact of genetic variation","volume":"238","author":"Nies","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0605","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.301.3.797","article-title":"Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors","volume":"301","author":"Enomoto","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0610","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1006\/bbrc.2001.4774","article-title":"Isolation of a family of organic anion transporters from human liver and kidney","volume":"283","author":"Sun","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0615","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1124\/mol.107.043117","article-title":"Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP","volume":"73","author":"Cropp","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0620","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/dmd.111.042036","article-title":"Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs","volume":"40","author":"Cheng","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0625","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/dmd.115.066944","article-title":"Diclofenac and its acyl glucuronide: determination of in vivo exposure in human subjects and Characterization as human drug transporter substrates in vitro","volume":"44","author":"Zhang","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0630","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.252049","article-title":"Organic anion transporter 2-mediated hepatic uptake contributes to the Clearance of high-permeability-low-Molecular-weight acid and zwitterion drugs: evaluation using 25 drugs","volume":"367","author":"Kimoto","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0635","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.117.245951","article-title":"Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug","volume":"364","author":"Bi","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0640","first-page":"1284","article-title":"Role of hepatic organic anion transporter 2 in the Pharmacokinetics of R- and S-Warfarin","volume":"15","author":"Bi","year":"2018","journal-title":"In Vitro Studies and Mechanistic Evaluation, Mol Pharm"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0645","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.21596","article-title":"Novel liver-specific organic anion transporter OAT7 that operates the exchange of sulfate conjugates for short chain fatty acid butyrate","volume":"45","author":"Shin","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0650","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/cpt.2558","article-title":"Drug disposition protein quantification in matched human jejunum and liver from donors with obesity","volume":"111","author":"Wegler","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0655","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/tpj.2015.55","article-title":"Variability in hepatic expression of organic anion transporter 7\/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors","volume":"16","author":"Emami Riedmaier","year":"2016","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0660","doi-asserted-by":"crossref","first-page":"G570","DOI":"10.1152\/ajpgi.00542.2007","article-title":"Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes","volume":"295","author":"Govindarajan","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0665","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/09687689709044322","article-title":"Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+\/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine","volume":"15","author":"Ritzel","year":"1998","journal-title":"Molecular Membrane Biology"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0670","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1074\/jbc.M007746200","article-title":"Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)","volume":"276","author":"Ritzel","year":"2001","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0675","doi-asserted-by":"crossref","first-page":"R1809","DOI":"10.1152\/ajpregu.00293.2007","article-title":"In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta, American journal of physiology","volume":"293","author":"Govindarajan","year":"2007","journal-title":"Regulatory, Integrative and Comparative Physiology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0680","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/09687860600942534","article-title":"Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3","volume":"24","author":"Smith","year":"2007","journal-title":"Molecular Membrane Biology"},{"issue":"27","key":"10.1016\/j.bcp.2024.116166_b0685","doi-asserted-by":"crossref","first-page":"25436","DOI":"10.1074\/jbc.M409454200","article-title":"The broadly selective human Na+\/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics","volume":"280","author":"Smith","year":"2005","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b0690","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-004-1687-6","article-title":"[18F]FLT-PET in oncology: current status and opportunities","volume":"31","author":"Been","year":"2004","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0695","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01213011-200502000-00004","article-title":"Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2","volume":"15","author":"Owen","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0700","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjp.0701775","article-title":"Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters","volume":"123","author":"Jarvis","year":"1998","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0705","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1124\/mol.105.018945","article-title":"Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3)","volume":"69","author":"Hu","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b0710","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1128\/JVI.02280-08","article-title":"Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance","volume":"83","author":"Ibarra","year":"2009","journal-title":"Journal of Virology"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0715","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2012.11.027","article-title":"Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection","volume":"58","author":"Rau","year":"2013","journal-title":"Journal of Hepatology"},{"issue":"14","key":"10.1016\/j.bcp.2024.116166_b0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411237","article-title":"Interactions of the anti-SARS-CoV-2 agents molnupiravir and Nirmatrelvir\/Paxlovid with human drug transporters","volume":"24","author":"Bakos","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0725","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch"},{"issue":"7\u20138","key":"10.1016\/j.bcp.2024.116166_b0730","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/00498250801927427","article-title":"Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins","volume":"38","author":"Young","year":"2008","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0735","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.RES.0000238359.18495.42","article-title":"Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH","volume":"99","author":"Barnes","year":"2006","journal-title":"Circulation Research"},{"issue":"16","key":"10.1016\/j.bcp.2024.116166_b0740","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1074\/jbc.M414337200","article-title":"Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes","volume":"280","author":"Baldwin","year":"2005","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b0745","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1349-7006.2007.00581.x","article-title":"Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides","volume":"98","author":"Endo","year":"2007","journal-title":"Cancer Science"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0750","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/cpt.2984","article-title":"Addressing the clinical importance of equilibrative nucleoside transporters in drug discovery and development","volume":"114","author":"Hau","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0755","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/156800911793743600","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)","volume":"11","author":"Santini","year":"2011","journal-title":"Current Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0760","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000151541","article-title":"Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines","volume":"54","author":"Namwat","year":"2008","journal-title":"Chemotherapy"},{"issue":"14","key":"10.1016\/j.bcp.2024.116166_b0765","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1128\/JVI.00629-11","article-title":"Host-based ribavirin resistance influences hepatitis C virus replication and treatment response","volume":"85","author":"Ibarra","year":"2011","journal-title":"Journal of Virology"},{"issue":"20","key":"10.1016\/j.bcp.2024.116166_b0770","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0775","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jcph.1412","article-title":"A phase 1, open-label, Parallel-group, single-dose trial of the Pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment","volume":"59","author":"Taylor","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0780","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/1078-0432.CCR-13-2293","article-title":"Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity","volume":"20","author":"Damaraju","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b0785","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.biocel.2013.06.022","article-title":"Multidrug and toxin extrusion proteins (MATE\/SLC47); role in pharmacokinetics","volume":"45","author":"Staud","year":"2013","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0790","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1016\/j.bbamem.2018.07.005","article-title":"Purification and reconstitution of polyspecific H(+)\/organic cation antiporter human MATE1","volume":"1860","author":"Kawasaki","year":"2018","journal-title":"Biochimica Et Biophysica Acta. Biomembranes"},{"issue":"50","key":"10.1016\/j.bcp.2024.116166_b0795","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0800","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2006030205","article-title":"Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2","volume":"17","author":"Masuda","year":"2006","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b0805","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.bcp.2008.07.005","article-title":"Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1\/hMATE1 and hOCT2\/hMATE1","volume":"76","author":"Sato","year":"2008","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0810","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bcp.2007.04.010","article-title":"Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\/H(+)-organic cation antiporters","volume":"74","author":"Tanihara","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0815","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b0820","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b0825","doi-asserted-by":"crossref","first-page":"e0202706","DOI":"10.1371\/journal.pone.0202706","article-title":"Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, oct) and multidrug and toxin extrusion proteins (MATE, mate)","volume":"13","author":"Ceckova","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0830","doi-asserted-by":"crossref","first-page":"C1669","DOI":"10.1152\/ajpcell.00202.2007","article-title":"Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction","volume":"293","author":"Qiu","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"Pt 3","key":"10.1016\/j.bcp.2024.116166_b0835","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1042\/bj20020512","article-title":"The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter","volume":"367","author":"Whetstine","year":"2002","journal-title":"Biochem J"},{"issue":"11","key":"10.1016\/j.bcp.2024.116166_b0840","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1167\/iovs.07-0288","article-title":"Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types","volume":"48","author":"Umapathy","year":"2007","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0845","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1186\/s12885-023-11257-8","article-title":"Correlation of toxicities and efficacies of pemetrexed with clinical factors and single-nucleotide polymorphisms: a prospective observational study","volume":"23","author":"Takeda","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2024.116166_b0850","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","article-title":"The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis","volume":"38","author":"Li","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0855","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.biocel.2013.01.018","article-title":"The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease","volume":"45","author":"Wee","year":"2013","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"14","key":"10.1016\/j.bcp.2024.116166_b0860","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1073\/pnas.94.14.7481","article-title":"hCTR1: a human gene for copper uptake identified by complementation in yeast","volume":"94","author":"Zhou","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0865","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1042\/BJ20070705","article-title":"Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake","volume":"407","author":"van den Berghe","year":"2007","journal-title":"Biochem J"},{"issue":"52","key":"10.1016\/j.bcp.2024.116166_b0870","doi-asserted-by":"crossref","first-page":"54221","DOI":"10.1074\/jbc.M411669200","article-title":"Mobilization of intracellular copper stores by the ctr2 vacuolar copper transporter","volume":"279","author":"Rees","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0875","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jn\/136.1.21","article-title":"Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status","volume":"136","author":"Kuo","year":"2006","journal-title":"The Journal of Nutrition"},{"issue":"13","key":"10.1016\/j.bcp.2024.116166_b0880","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1158\/1078-0432.CCR-09-0311","article-title":"Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and Carboplatin","volume":"15","author":"Blair","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.bcp.2024.116166_b0885","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0890","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2011.06.011","article-title":"Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy","volume":"75","author":"Chen","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b0895","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2011.04.025","article-title":"Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy","volume":"122","author":"Lee","year":"2011","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b0900","first-page":"1409","article-title":"Association of copper transporter expression with platinum resistance in epithelial ovarian cancer","volume":"33","author":"Yoshida","year":"2013","journal-title":"Anticancer Research"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b0905","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/humu.24418","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"43","author":"Dean","year":"2022","journal-title":"Human Mutation"},{"key":"10.1016\/j.bcp.2024.116166_b0910","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","article-title":"ABC family transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"issue":"23","key":"10.1016\/j.bcp.2024.116166_b0915","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/1873-3468.13967","article-title":"An inventory of lysosomal ABC transporters","volume":"594","author":"Szakacs","year":"2020","journal-title":"FEBS Letters"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0920","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCRESAHA.112.276667","article-title":"ABCC6 localizes to the mitochondria-associated membrane","volume":"111","author":"Martin","year":"2012","journal-title":"Circulation Research"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0925","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1124\/mol.108.052209","article-title":"Mrp1 localization and function in cardiac mitochondria after doxorubicin","volume":"75","author":"Jungsuwadee","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bcp.2024.116166_b0930","first-page":"6786245","article-title":"ABC transporter subfamily D: distinct differences in behavior between ABCD1-3 and ABCD4 in Subcellular localization","volume":"2016","author":"Kawaguchi","year":"2016","journal-title":"Function, and Human Disease, BioMed Research International"},{"key":"10.1016\/j.bcp.2024.116166_b0935","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-biochem-011520-105201","article-title":"Structural and mechanistic principles of ABC transporters","volume":"89","author":"Thomas","year":"2020","journal-title":"Annual Review of Biochemistry"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0940","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"4617","key":"10.1016\/j.bcp.2024.116166_b0945","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.6137059","article-title":"Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines","volume":"221","author":"Kartner","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116166_b0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.018","article-title":"Drugs and hepatic transporters: a review","volume":"154","author":"Jetter","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.bcp.2024.116166_b0955","article-title":"P-glycoprotein: one mechanism","volume":"10","author":"Seelig","year":"2020","journal-title":"Many Tasks and the Consequences for Pharmacotherapy of Cancers, Frontiers in Oncology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0960","first-page":"25","article-title":"The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability, european journal of pharmaceutical sciences : official journal of the european federation for","volume":"21","author":"Chan","year":"2004","journal-title":"Pharmaceutical Sciences"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b0965","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1073\/pnas.85.12.4486","article-title":"A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells","volume":"85","author":"Pastan","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"21","key":"10.1016\/j.bcp.2024.116166_b0970","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2024.116166_b0975","first-page":"S23","article-title":"Importance of hepatic transporters in clinical disposition of drugs and their metabolites","volume":"56","author":"Patel","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2024.116166_b0980","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","volume":"201","author":"Cascorbi","year":"2011","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b0985","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(02)00155-6","article-title":"MDR1 gene expression in hepatocellular carcinoma and the peritumoral liver of patients with and without cirrhosis","volume":"186","author":"Grude","year":"2002","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b0990","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(03)00096-5","article-title":"Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis","volume":"38","author":"Zollner","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b0995","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bcpt.13780","article-title":"Drug metabolism and drug transport of the 100 most prescribed oral drugs","volume":"131","author":"Iversen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"14","key":"10.1016\/j.bcp.2024.116166_b1000","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143524","article-title":"Expression of chemoresistance-associated ABC proteins in Hepatobiliary, pancreatic and gastrointestinal cancers","volume":"14","author":"Marin","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2024.116166_b1010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug Interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.bcp.2024.116166_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100743","article-title":"Multidrug resistance proteins (MRPs): structure, function and the overcoming of cancer multidrug resistance","volume":"54","author":"Wang","year":"2021","journal-title":"Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/cpt.2644","article-title":"Transporters in drug development: international transporter consortium update on Emerging transporters of clinical importance","volume":"112","author":"Zamek-Gliszczynski","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.bcp.2024.116166_b1025","doi-asserted-by":"crossref","unstructured":"G. Jedlitschky, I. Leier, U. Buchholz, J. Hummel-Eisenbeiss, B. Burchell, D. Keppler, ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2, Biochem J 327 (Pt 1)(Pt 1) (1997) 305-10.","DOI":"10.1042\/bj3270305"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-2000-9391","article-title":"Hepatic secretion of conjugated drugs and endogenous substances","volume":"20","author":"Keppler","year":"2000","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2000-9426","article-title":"Hepatic transport of bile salts","volume":"20","author":"Kullak-Ublick","year":"2000","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.taap.2004.10.012","article-title":"Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense","volume":"204","author":"Leslie","year":"2005","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/03602530903491741","article-title":"ABCC2\/Abcc2: a multispecific transporter with dominant excretory functions","volume":"42","author":"Jemnitz","year":"2010","journal-title":"Drug Metabolism Reviews"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1248\/bpb.34.433","article-title":"Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib","volume":"34","author":"Shibayama","year":"2011","journal-title":"Biol Pharm Bull"},{"issue":"13","key":"10.1016\/j.bcp.2024.116166_b1055","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-15-0280","article-title":"Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a\/1b","volume":"75","author":"Vasilyeva","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ijc.1498","article-title":"Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma","volume":"94","author":"Nies","year":"2001","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/FTD.0b013e31819c67e5","article-title":"Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer","volume":"31","author":"Yokoo","year":"2009","journal-title":"Therapeutic Drug Monitoring"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b1070","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1506","article-title":"Positron emission tomography imaging of [(11) C]Rosuvastatin hepatic concentrations and Hepatobiliary transport in humans in the absence and presence of cyclosporin a","volume":"106","author":"Billington","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1075","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/jhep.2001.23501","article-title":"Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver","volume":"33","author":"Soroka","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1080","doi-asserted-by":"crossref","first-page":"G165","DOI":"10.1152\/ajpgi.00362.2002","article-title":"A common dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2)","volume":"284","author":"Keitel","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b1085","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1124\/dmd.111.041012","article-title":"Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease","volume":"39","author":"Hardwick","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"14","key":"10.1016\/j.bcp.2024.116166_b1090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147947","article-title":"Protein abundance of drug transporters in human hepatitis C livers","volume":"23","author":"Drozdzik","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1600-0676.2001.021004247.x","article-title":"Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis","volume":"21","author":"Oswald","year":"2001","journal-title":"Liver"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cpt.66","article-title":"Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis","volume":"97","author":"Ferslew","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b1105","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/dmd.114.062703","article-title":"Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis","volume":"43","author":"Canet","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2024.116166_b1110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.04.019","article-title":"Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: involvement of SREBP-mediated gene regulation","volume":"452","author":"Kobayashi","year":"2013","journal-title":"International Journal of Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41401-019-0266-0","article-title":"Rifampicin induces clathrin-dependent endocytosis and ubiquitin-proteasome degradation of MRP2 via oxidative stress-activated PKC-ERK\/JNK\/p38 and PI3K signaling pathways in HepG2 cells","volume":"41","author":"Xu","year":"2020","journal-title":"Acta Pharmacologica Sinica"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1120","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/092986711794839197","article-title":"Structural and functional properties of human multidrug resistance protein 1 (MRP1\/ABCC1)","volume":"18","author":"He","year":"2011","journal-title":"Current Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b1125","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/path.1379","article-title":"High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease","volume":"200","author":"Ros","year":"2003","journal-title":"The Journal of Pathology"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b1130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/labinvest.3780411","article-title":"Tissue distribution and induction of human multidrug resistant protein 3","volume":"82","author":"Scheffer","year":"2002","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b1135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1517\/17425255.2015.981152","article-title":"New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition","volume":"11","author":"van der Schoor","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1140","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/jpet.106.110106","article-title":"Evaluation of the role of multidrug resistance-associated protein (mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-\/- and Abcc4-\/- mice","volume":"319","author":"Zamek-Gliszczynski","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"10.1016\/j.bcp.2024.116166_b1145","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1073\/pnas.0502530102","article-title":"Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception","volume":"102","author":"Zelcer","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"24","key":"10.1016\/j.bcp.2024.116166_b1150","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1158\/1078-0432.CCR-08-1609","article-title":"Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate","volume":"14","author":"Vlaming","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1155","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s12253-018-0386-8","article-title":"Immunohistochemical assessment of the expression of Biliary transportation proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma","volume":"25","author":"Cirqueira","year":"2019","journal-title":"Pathology Oncology Research : POR"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1160","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.31088","article-title":"MRP3-mediated chemoresistance in Cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression","volume":"72","author":"Lozano","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b1165","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.117.110593","article-title":"Leflunomide increases hepatic exposure to methotrexate and its metabolite by differentially regulating multidrug resistance-associated protein Mrp2\/3\/4 transporters via Peroxisome proliferator-activated receptor alpha activation","volume":"93","author":"Wang","year":"2018","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/bdd.1936","article-title":"The molecular mechanism underlying the induction of hepatic MRP3 expression and function by omeprazole","volume":"36","author":"Pan","year":"2015","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11096-019-00958-5","article-title":"Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis","volume":"42","author":"Wang","year":"2020","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b1180","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2003.50331","article-title":"Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane","volume":"38","author":"Rius","year":"2003","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b1185","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1478-3231.2007.01506.x","article-title":"Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis","volume":"27","author":"Zollner","year":"2007","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1190","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1734-1140(12)70888-5","article-title":"Expression of genes involved in xenobiotic metabolism and transport in end-stage liver disease: up-regulation of ABCC4 and CYP1B1","volume":"64","author":"Kurzawski","year":"2012","journal-title":"Pharmacological Reports : PR"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b1195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2133\/dmpk.25.190","article-title":"Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters","volume":"25","author":"Ogasawara","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1389200216666151103115454","article-title":"Bile acids in physiology, pathology and Pharmacology","volume":"17","author":"Marin","year":"2015","journal-title":"Curr Drug Metab"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1205","doi-asserted-by":"crossref","first-page":"G640","DOI":"10.1152\/ajpgi.00354.2005","article-title":"Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione","volume":"290","author":"Rius","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b1210","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.114.057554","article-title":"Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat","volume":"42","author":"Ferslew","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1215","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1124\/jpet.113.207472","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.bcp.2024.116166_b1220","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/dmd.121.000430","article-title":"Comparative hepatic and intestinal efflux transport of statins","volume":"49","author":"Deng","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"51","key":"10.1016\/j.bcp.2024.116166_b1225","doi-asserted-by":"crossref","first-page":"32939","DOI":"10.1021\/acsomega.0c03930","article-title":"Contribution of uptake and efflux transporters to Oral Pharmacokinetics of furosemide","volume":"5","author":"Chapa","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bcp.2024.116166_b1230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2017.06.024","article-title":"Suppression of the ATP-binding cassette transporter ABCC4 impairs neuroblastoma tumour growth and sensitises to irinotecan in vivo","volume":"83","author":"Murray","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b1235","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3851\/IMP1468","article-title":"Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4","volume":"14","author":"Clemente","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bcp.2024.116166_b1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.015","article-title":"Multidrug resistance-associated protein 4 in pharmacology: overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics","volume":"231","author":"Berthier","year":"2019","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b1245","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hiv.12072","article-title":"Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration","volume":"14","author":"Bickel","year":"2013","journal-title":"HIV Medicine"},{"issue":"16","key":"10.1016\/j.bcp.2024.116166_b1250","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bcp.2024.116166_b1255","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1349-7006.2004.tb03244.x","article-title":"Comparative analysis of ATP-binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma","volume":"95","author":"Moustafa","year":"2004","journal-title":"Cancer Science"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1260","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep.24682","article-title":"Reseau Centre de ressources biologiques foie, adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs","volume":"55","author":"Borel","year":"2012","journal-title":"Hepatology"},{"issue":"39","key":"10.1016\/j.bcp.2024.116166_b1265","doi-asserted-by":"crossref","first-page":"30069","DOI":"10.1074\/jbc.M005463200","article-title":"The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides","volume":"275","author":"Jedlitschky","year":"2000","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b1270","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/1535-7163.MCT-04-0291","article-title":"The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites","volume":"4","author":"Pratt","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.bcp.2024.116166_b1275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/labinvest.3780444","article-title":"MRP6 (ABCC6) detection in normal human tissues and tumors","volume":"82","author":"Scheffer","year":"2002","journal-title":"Laboratory Investigation; a Journal of Technical Methods and Pathology"},{"issue":"21","key":"10.1016\/j.bcp.2024.116166_b1280","first-page":"6172","article-title":"Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6)","volume":"62","author":"Belinsky","year":"2002","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b1285","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1007\/s11033-022-07872-6","article-title":"ABCC6P1 pseudogene induces ABCC6 upregulation and multidrug resistance in breast cancer","volume":"49","author":"Hashemi","year":"2022","journal-title":"Molecular Biology Reports"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1290","doi-asserted-by":"crossref","first-page":"e0192180","DOI":"10.1371\/journal.pone.0192180","article-title":"ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells","volume":"13","author":"Eadie","year":"2018","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bcp.2024.116166_b1295","first-page":"5337","article-title":"A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance","volume":"58","author":"Allikmets","year":"1998","journal-title":"Cancer Res"},{"issue":"2\u20133","key":"10.1016\/j.bcp.2024.116166_b1300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.placenta.2006.03.009","article-title":"Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta","volume":"28","author":"Serrano","year":"2007","journal-title":"Placenta"},{"issue":"26","key":"10.1016\/j.bcp.2024.116166_b1305","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.bcp.2024.116166_b1310","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.bcp.2024.116166_b1315","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/mol.111.075143","article-title":"Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta","volume":"81","author":"Blazquez","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116166_b1320","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.64.3.610","article-title":"Breast cancer resistance protein exports sulfated estrogens but not free estrogens","volume":"64","author":"Imai","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"Pt 2","key":"10.1016\/j.bcp.2024.116166_b1325","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1042\/BJ20040791","article-title":"Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2)","volume":"385","author":"Janvilisri","year":"2005","journal-title":"Biochem J"},{"issue":"23","key":"10.1016\/j.bcp.2024.116166_b1330","doi-asserted-by":"crossref","first-page":"24218","DOI":"10.1074\/jbc.M313599200","article-title":"The stem cell marker Bcrp\/ABCG2 enhances hypoxic cell survival through interactions with heme","volume":"279","author":"Krishnamurthy","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bcp.2024.116166_b1335","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-006-0134-x","article-title":"ATP-binding cassette, subfamily G (ABCG family)","volume":"453","author":"Kusuhara","year":"2007","journal-title":"Pflugers Arch"},{"issue":"7","key":"10.1016\/j.bcp.2024.116166_b1340","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/138920010792927325","article-title":"Structure and function of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"11","author":"Ni","year":"2010","journal-title":"Curr Drug Metab"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b1345","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1128\/AAC.00449-09","article-title":"Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers","volume":"53","author":"Pham","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"10.1016\/j.bcp.2024.116166_b1350","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1124\/dmd.114.059832","article-title":"Differential expression of drug uptake and efflux transporters in japanese patients with hepatocellular carcinoma","volume":"42","author":"Namisaki","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.bcp.2024.116166_b1355","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1124\/dmd.107.016170","article-title":"Induction of hepatobiliary efflux transporters in acetaminophen-induced acute liver failure cases","volume":"35","author":"Barnes","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.bcp.2024.116166_b1360","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the international transporter consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:16:32Z","timestamp":1731456992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":272,"alternative-id":["S0006295224001497"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116166","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116166"}}